Logo image of NSCI.CA

NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis

TSX-V:NSCI - TSX Venture Exchange - CA63000Y1034 - Common Stock - Currency: CAD

0.26  +0.01 (+1.96%)

Fundamental Rating

3

Taking everything into account, NSCI scores 3 out of 10 in our fundamental rating. NSCI was compared to 16 industry peers in the Health Care Equipment & Supplies industry. NSCI may be in some trouble as it scores bad on both profitability and health. NSCI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NSCI has reported negative net income.
NSCI had a negative operating cash flow in the past year.
In the past 5 years NSCI always reported negative net income.
In the past 5 years NSCI reported 4 times negative operating cash flow.
NSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFNSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.71%, NSCI belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
The Return On Equity of NSCI (-36.72%) is better than 87.50% of its industry peers.
Industry RankSector Rank
ROA -16.71%
ROE -36.72%
ROIC N/A
ROA(3y)-16.32%
ROA(5y)-14.21%
ROE(3y)-34.86%
ROE(5y)-27.68%
ROIC(3y)N/A
ROIC(5y)N/A
NSCI.CA Yearly ROA, ROE, ROICNSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60

1.3 Margins

NSCI has a worse Gross Margin (23.90%) than 68.75% of its industry peers.
NSCI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-40.32%
GM growth 5Y-26.36%
NSCI.CA Yearly Profit, Operating, Gross MarginsNSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60

More info and screens

2

2. Health

2.1 Basic Checks

NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NSCI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NSCI has more shares outstanding
Compared to 1 year ago, NSCI has a worse debt to assets ratio.
NSCI.CA Yearly Shares OutstandingNSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
NSCI.CA Yearly Total Debt VS Total AssetsNSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.07, we must say that NSCI is in the distress zone and has some risk of bankruptcy.
NSCI has a better Altman-Z score (0.07) than 75.00% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that NSCI is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.61, NSCI is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z 0.07
ROIC/WACCN/A
WACC6.2%
NSCI.CA Yearly LT Debt VS Equity VS FCFNSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.30 indicates that NSCI should not have too much problems paying its short term obligations.
NSCI's Current ratio of 1.30 is in line compared to the rest of the industry. NSCI outperforms 50.00% of its industry peers.
A Quick Ratio of 0.94 indicates that NSCI may have some problems paying its short term obligations.
The Quick ratio of NSCI (0.94) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.94
NSCI.CA Yearly Current Assets VS Current LiabilitesNSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

6

3. Growth

3.1 Past

NSCI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.00%.
Looking at the last year, NSCI shows a very strong growth in Revenue. The Revenue has grown by 40.80%.
NSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.71% yearly.
EPS 1Y (TTM)-60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)40.8%
Revenue growth 3Y53.48%
Revenue growth 5Y27.71%
Sales Q2Q%50.23%

3.2 Future

Based on estimates for the next years, NSCI will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.54% on average per year.
Based on estimates for the next years, NSCI will show a quite strong growth in Revenue. The Revenue will grow by 14.81% on average per year.
EPS Next Y65.28%
EPS Next 2Y41.42%
EPS Next 3Y31.09%
EPS Next 5Y19.54%
Revenue Next Year58.22%
Revenue Next 2Y28.19%
Revenue Next 3Y20.58%
Revenue Next 5Y14.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NSCI.CA Yearly Revenue VS EstimatesNSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
NSCI.CA Yearly EPS VS EstimatesNSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2026 2027 2028 0 0.05 -0.05 -0.1 -0.15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NSCI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSCI.CA Price Earnings VS Forward Price EarningsNSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSCI.CA Per share dataNSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

NSCI's earnings are expected to grow with 31.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y31.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NSCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANALYSIS SCIENTIFIC CORP

TSX-V:NSCI (5/8/2025, 7:00:00 PM)

0.26

+0.01 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-24 2025-04-24/amc
Earnings (Next)05-28 2025-05-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners4.07%
Ins Owner ChangeN/A
Market Cap29.44M
Analysts80
Price Target1.07 (311.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)34.9%
Min Revenue beat(2)16.28%
Max Revenue beat(2)53.52%
Revenue beat(4)4
Avg Revenue beat(4)30.32%
Min Revenue beat(4)2.14%
Max Revenue beat(4)53.52%
Revenue beat(8)5
Avg Revenue beat(8)8.38%
Revenue beat(12)7
Avg Revenue beat(12)3.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.74%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)0.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 16.17
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.38
BVpS0.2
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.71%
ROE -36.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.9%
FCFM N/A
ROA(3y)-16.32%
ROA(5y)-14.21%
ROE(3y)-34.86%
ROE(5y)-27.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-40.32%
GM growth 5Y-26.36%
F-Score5
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.86%
Cap/Sales 5.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 0.94
Altman-Z 0.07
F-Score5
WACC6.2%
ROIC/WACCN/A
Cap/Depr(3y)123.44%
Cap/Depr(5y)181.14%
Cap/Sales(3y)21.29%
Cap/Sales(5y)27.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y65.28%
EPS Next 2Y41.42%
EPS Next 3Y31.09%
EPS Next 5Y19.54%
Revenue 1Y (TTM)40.8%
Revenue growth 3Y53.48%
Revenue growth 5Y27.71%
Sales Q2Q%50.23%
Revenue Next Year58.22%
Revenue Next 2Y28.19%
Revenue Next 3Y20.58%
Revenue Next 5Y14.81%
EBIT growth 1Y72.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-86.97%
EBIT Next 3Y1.92%
EBIT Next 5Y5.55%
FCF growth 1Y79.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.04%
OCF growth 3YN/A
OCF growth 5YN/A